Life sciences innovations often involve complex technologies, extensive research, and highly competitive markets. Protecting these innovations requires a legal strategy that aligns with both the science behind the invention and the goals of the organization developing it.

At Gearhart Law, we assist biotechnology companies, pharmaceutical and biopharmaceutical businesses, medical device innovators, research institutions, and startups with patent matters involving life sciences technologies. Our team of attorneys work with clients at various stages of growth, from early-stage companies seeking intellectual property protection to established organizations managing and expanding patent portfolios.

Let’s Build Something Together: Call 908.273.0700

What Is a Life Sciences Patent and Why Does It Matter?

A life sciences patent is a form of intellectual property protection granted by the U.S. Patent and Trademark Office (USPTO) for novel, non-obvious, and useful innovations in biology, medicine, and related sciences. This includes new drug compounds, biologic therapies, medical device innovations, diagnostic methods, and biotechnology processes.

For the businesses and researchers we represent, a patent is not just a legal document. It is a business asset. It gives you the right to exclude competitors from your market, forms the foundation of your licensing strategy, and is often the primary collateral that makes a biotech startup investable. Investors in early-stage life sciences companies expect to see a defensible patent position before committing capital, and they will have it reviewed by sophisticated IP counsel.

The stakes are high, the science is complex, and the legal landscape evolves quickly. The Mayo/Alice framework under 35 U.S.C. § 101, evolving USPTO guidance on biologics and diagnostic methods, and the ever-present threat of Inter Partes Review (IPR) all shape what protection you can get and how durable it will be. Getting it right requires counsel with genuine technical depth and attorneys who understand the science, not just the law.

New Jersey Life Sciences Patents: Jurisdiction and Key Legal Context

Patent law is federal; 35 U.S.C. governs patent rights nationwide, and the USPTO reviews all applications regardless of where you are located. However, where you operate and where disputes arise matters significantly for enforcement.

  • The District of New Jersey (D.N.J.) is one of the most active federal courts in the country for pharmaceutical patent litigation, due to the concentration of major pharma companies headquartered in New Jersey. Hatch-Waxman patent litigation, the framework governing generic drug challenges under 21 U.S.C. § 355(j), is frequently litigated in D.N.J. If you are a pharmaceutical or biopharmaceutical company with products on the market, understanding this venue is important.
  • Statute of Limitations: Patent infringement claims in the U.S. must be brought within six years of the alleged infringement under 35 U.S.C. § 286. Damages are limited to the six-year period before filing. There is no statute of limitations that bars filing a lawsuit, but laches may apply in equity.
  • New Jersey Courts: The U.S. District Court for the District of New Jersey sits in Newark, Trenton, and Camden. The Federal Circuit hears all patent appeals. For state-law trade secret claims that may accompany patent matters, the New Jersey Superior Court applies the New Jersey Trade Secrets Act (N.J.S.A. 56:15-1 et seq.).
  • IP Litigation: When life sciences patents are challenged, through IPR proceedings before the PTAB, Hatch-Waxman litigation in D.N.J., or infringement actions, the stakes are existential for many companies. Our team has direct experience in PTAB proceedings including Inter Partes Review and Post Grant Review. If your core patent is under attack, or if you need to challenge a competitor’s, we have handled that work.

How the Life Sciences Patent Process Works

Here is what a typical engagement looks like from first call to granted patent and beyond.

  1. Initial Consultation & Invention Assessment: We learn the science, assess patentability, review the competitive landscape, and advise on timing. We look at whether a provisional application makes sense, and we identify any publication or on-sale bar risks.
  2. Prior Art Search: We conduct a thorough search of existing patents and scientific literature. In life sciences, this includes reviewing the biotech and pharmaceutical patent databases, not just general patent search tools.
  3. Application Drafting: Our Ph.D.-trained attorneys draft the specification and claims. For life sciences, this means technically rigorous descriptions of biological mechanisms, chemical structures, or device functionality, written to maximize claim scope while anticipating examiner challenges.
  4. USPTO Filing & Prosecution: We file the application and manage the examination process. Life sciences applications often involve substantive back-and-forth with examiners; our team responds with technical and legal arguments grounded in the science.
  5. Office Action Responses: If the examiner raises objections or rejections, we respond with amendments, arguments, or both. § 101 eligibility rejections in life sciences require particular skill to overcome.
  6. Grant or Appeal: When the application is allowed, the patent issues. If allowance is refused, we can appeal to the Patent Trial and Appeal Board (PTAB).
  7. Post-Grant Strategy: A granted patent is the beginning of a business asset, not the end of a legal process. We assist clients with continuation applications, reissues, licensing, enforcement, and patent portfolio management.

Contact Us To Get Started

Life Sciences Intellectual Property Services

Gearhart Law works with businesses, research institutions, and emerging companies to help protect and maximize the value of their intellectual property assets. Our life sciences intellectual property services may include:

  • Patent preparation, filing, and prosecution for biotechnology, pharmaceutical, medical device, and healthcare innovations
  • Patent portfolio development and management strategies designed to support long-term business objectives
  • Intellectual property due diligence for investors, startups, mergers, acquisitions, and licensing opportunities
  • Patentability, freedom-to-operate, and competitive landscape analyses
  • Trademark protection for life sciences products, brands, and technologies
  • Licensing, technology transfer, and commercialization support
  • Intellectual property enforcement and dispute resolution when patent or trademark rights are challenged
  • Strategic intellectual property planning for startups, university spinouts, and established life sciences organizations

Our team works with clients across a broad range of life sciences industries, including pharmaceuticals, biotechnology, medical devices, healthcare technologies, diagnostics, and related research-driven fields. Whether developing a new invention, expanding a patent portfolio, or preparing intellectual property assets for investment or commercialization, we help clients navigate the legal considerations associated with protecting innovation.

What Good Life Sciences IP Strategy Delivers

The value of life sciences IP protection is measured in business outcomes, not just legal wins. Companies that work with experienced life sciences IP counsel may be able to:

  • Secure foundational patents that become the basis of licensing revenue streams
  • Build a portfolio strong enough to survive investor due diligence in Series A, B, and beyond
  • Protect a market position for up to 20 years from patent filing (plus potential Hatch-Waxman extensions for pharmaceutical products)
  • Obtain freedom-to-operate clearance that reduces risk before major R&D investment
  • Defend against IPR challenges that threaten core product patents
  • Structure IP in a way that supports acquisition or partnership transactions

We do not guarantee specific outcomes. Patent allowance, enforceability, and litigation results depend on the specific facts, science, prior art landscape, and legal arguments involved. What we do guarantee is that our team will bring genuine technical depth and decades of combined experience to your matter.

Why Choose Gearhart Law for Life Sciences Patent

Life sciences innovations often involve sophisticated technologies, extensive research, and significant investments in development. Protecting those innovations requires intellectual property counsel that can understand both the science behind the invention and the legal strategies available to protect it.

  • Combined Attorney Experiences: This depth of technical knowledge is reflected throughout our team. T. Benjamin (Ben) Schroeder, Ph.D., Esq. brings advanced training in biochemistry and biophysics, along with decades of patent prosecution experience and prior service as a USPTO Patent Examiner. Joe Runge, J.D., M.S. has an extensive background in university technology transfer and technology commercialization. James Klobucar, Esq. contributes a strong foundation in biochemistry, molecular biology, and chemistry. Together, our attorneys bring diverse scientific, technical, and legal experience that supports clients across a broad range of life sciences innovations.
  • Industry-Focused Perspective: We work with a broad range of life sciences innovators, including biotechnology startups, pharmaceutical companies, medical device developers, research institutions, and university spinouts. This experience provides insight into the intellectual property challenges that often arise at different stages of development and commercialization.
  • Strategic Patent Portfolio Development: Patent protection is often about more than a single application. We help clients build and manage intellectual property portfolios that support long-term business objectives, investment opportunities, licensing efforts, and future growth.
  • Personalized Client Service: As a boutique intellectual property firm, we emphasize direct attorney involvement and collaborative client relationships. Our team works closely with inventors, researchers, entrepreneurs, and business leaders to develop intellectual property strategies tailored to their technologies and goals.

Contact Us To Get Started

Frequently Asked Questions About Life Sciences Patents

1. Can a biotech startup file a patent before they have funding?

Yes, and for many early-stage biotech companies, this is the right sequence rather than an exception. A provisional patent application establishes an early priority date and gives the invention patent-pending status for up to 12 months, without requiring the full cost and formality of a non-provisional filing. This matters because in the U.S., patent rights generally go to whoever files first, so establishing that priority date early can protect the invention before it is discussed with investors, presented at a conference, published in a journal, or shared with a potential partner or collaborator.

Filing a provisional before raising capital also gives the company more freedom during fundraising conversations. Investors and potential licensing partners often expect to see some IP protection in place before committing significant time or capital, and a filed provisional signals that the invention has been formally staked out even if the full non-provisional application, with its more detailed claims and specification, is still being developed. The 12-month window also gives the company time to refine the invention, gather additional data, or bring on a co-founder or research partner before the more expensive non-provisional filing is due.

2. How long does a pharmaceutical patent last in the U.S.?

Most U.S. utility patents, including those covering pharmaceutical compounds and methods, last 20 years from the filing date of the non-provisional application. For pharmaceutical products specifically, this term can be extended through Patent Term Extension (PTE) under the Hatch-Waxman Act, which compensates for time lost during the FDA regulatory review process. Because drug approval can take many years, a portion of the original patent term may effectively be consumed before the product ever reaches the market, and PTE is designed to restore some of that lost commercial life.

PTE is not automatic and is subject to specific limitations. Only one patent per approved product is typically eligible for extension, the extension is capped at five years, and the total remaining patent term after extension cannot exceed 14 years from the date of FDA approval. Calculating and applying for PTE correctly requires careful attention to filing deadlines and documentation of the regulatory review timeline, which is why this is usually handled as part of a broader patent portfolio and regulatory strategy rather than as a standalone filing task.

3. What is a freedom-to-operate analysis and when do I need one?

A freedom-to-operate (FTO) analysis evaluates whether making, using, selling, or importing a product or process would infringe on patents already held by others. It is a distinct exercise from patentability. A product or method can be entirely patentable in its own right, meaning it is novel and non-obvious, while still infringing on someone else’s existing patent claims. An FTO analysis specifically looks at the current patent landscape to identify that risk before it becomes a legal or business problem.

FTO analyses are most valuable when performed before a major financial commitment, since the cost of discovering a blocking patent goes up significantly the later it is found. Common triggers include before beginning substantial R&D investment in a new compound or device, before a product launch or clinical trial, during due diligence for an acquisition or licensing deal, and before entering a new geographic market where the patent landscape may differ. If an FTO analysis identifies a blocking patent, the company still has options, including designing around the patent, negotiating a license, or challenging the patent’s validity, but those options are far more manageable when identified early rather than after launch.

4. Can I patent a diagnostic method or biomarker?

Potentially, but diagnostic and biomarker inventions face a distinct and well-documented eligibility challenge under U.S. patent law that most other life sciences inventions do not face in the same way. Under the framework set out in Mayo Collaborative Services v. Prometheus Laboratories, claims that simply identify a correlation between a biomarker and a disease state, without more, are often treated as an unpatentable law of nature or natural phenomenon, even if the underlying discovery is genuinely novel and clinically valuable.

The path to patentability generally requires the claims to go beyond the observation itself. This can mean incorporating a specific, non-conventional method of detecting or measuring the biomarker, a particular treatment step that follows from the diagnostic result, or a technical application that transforms the natural correlation into something more concrete than an observation about biology. Because USPTO examination guidance and Federal Circuit case law in this area continue to evolve, claim drafting strategy for diagnostic and biomarker inventions needs to be built around the current state of that case law at the time of filing, not a fixed formula, which makes early involvement from counsel with specific experience in this area particularly important.

5. How can a life sciences patent attorney help?

A life sciences patent attorney supports the full lifecycle of an invention, not just the initial filing. Early on, this includes assessing patentability, evaluating publication and on-sale bar risks before the invention is disclosed publicly, and advising on whether a provisional filing makes sense given the company’s timeline and funding stage. During prosecution, the attorney drafts the specification and claims with enough technical precision to withstand examiner scrutiny, and responds to office actions, including the § 101 eligibility rejections that are especially common in diagnostics, biologics, and other life sciences subfields.

Beyond the initial grant, a life sciences patent attorney also supports the business side of the IP asset. This includes building a broader patent portfolio through continuation applications as the science develops, conducting freedom-to-operate and competitive landscape analyses before major investment decisions, supporting licensing and technology transfer agreements, and representing the company in IPR or PTAB proceedings if a patent is challenged or needs to be challenged. Because life sciences patents often serve as the primary asset that makes a company investable or acquirable, having attorneys involved early and consistently, rather than brought in only at filing time, tends to produce a stronger and more defensible portfolio over the company’s lifecycle.

Contact Our Life Sciences IP Attorneys Today

Whether you are developing a new therapeutic, diagnostic tool, medical device, biotechnology platform, pharmaceutical formulation, or other breakthrough technology, securing intellectual property protection early can play an important role in preserving the value of your work and supporting future growth.

At Gearhart Law, our team works with innovators, researchers, startups, and established companies to develop patent strategies tailored to their goals and technologies. Contact us at 908.273.0700 to schedule a consultation and discuss how to protect your life sciences innovation.